Back to Amgen

Amgen News

AMGN

Amgen Clarifies Non‑GAAP Restructuring Exclusions

Amgen (AMGN) says restructuring costs are excluded from non‑GAAP measures and reports no new restructuring actions. What investors should know.

AMGN

Amgen Reports Material Cybersecurity Breach

Amgen (AMGN) discloses material cybersecurity breach exposing proprietary and patient data; investors weigh legal, regulatory and operational risks.

AMGN

Amgen CFO Griffith to Retire in 2026 — Successor Named

Amgen (AMGN) CFO Peter Griffith will retire in 2026; Dittrich named successor. Key implications for capital allocation, debt, pipeline and investor risk.

AMGN

Amgen Issues $4B Senior Notes Maturing to 2056

Amgen (AMGN) raised $4B via senior notes maturing to 2056 on Feb 19, 2026. The issuance aligns with Amgen’s capital-allocation and debt-management plans.

AMGN

Amgen Reports Restructuring Charges, Intangible Impairments

Amgen (AMGN) discloses restructuring charges and intangible asset impairments in filings on 2025-11-04; read implications for financials and strategy.

AMGN

Amgen Raises Q3 2025 Dividend 6% to $2.38

Amgen (AMGN) declares $2.38 dividend for Q3 2025, a 6% YoY increase. Investors should weigh dividend growth against patent pressure and pipeline catalysts.

AMGN

Amgen Q3 2025: Revenue +12%, EPS +14%

Amgen (AMGN) posts 12% revenue and 14% EPS growth in Q3 2025. Read the drivers, pipeline updates and key risks for investors.

AMGN

AMGN: TEZSPIRE4 FDA Approval; MariTide & Repatha

AMGN: FDA approves TEZSPIRE4; MariTide enters Phase 3 and Repatha advances in 2025. Investor-focused analysis of growth, patents, and risks.